TrialAnnals of oncology : official journal of the European Society for Medical Oncology2013

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.

J D Wolchok et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.